Premature Oral Aging (Emerging Construct) – Cannabis Research

Premature Oral Aging (Emerging Construct) Research Dashboard

Loading research dashboard…

Loading Primary Studies…

Loading Related Studies…

Overview - Premature Oral Aging (Emerging Construct)

Description of Premature Oral Aging (Emerging Construct)

Premature Oral Aging — Emerging Construct


Based on the work of Alethéia B. Pablos and Guilherme Arthur Martins (2026).


Premature Oral Aging describes a clinical pattern in which the structures of the oral cavity exhibit degenerative changes that are disproportionate to a person’s chronological age. Rather than reflecting a single disease entity, it represents a multifactorial convergence of behavioral, psychosocial, neurobiological, and pharmacological influences that accelerate tissue breakdown and functional decline.


Clinically, this may present as early enamel wear, dentin hypersensitivity, periodontal degradation, temporomandibular dysfunction, xerostomia, and altered salivary quality, often resembling patterns typically seen in significantly older individuals. These changes are increasingly observed in younger populations.


At its core, this construct reflects dysregulation across interconnected systems, particularly involving:



  • Chronic stress and heightened sympathetic activity

  • Sleep disruption and circadian instability

  • Bruxism (both waking and sleep-related)

  • Psychosocial strain (e.g., anxiety, depression)

  • Behavioral and lifestyle factors (e.g., digital overuse, dietary patterns, substance exposure)

  • Medication effects (including antidepressants, anxiolytics, and stimulants)


These factors collectively contribute to a state of inflammaging, autonomic imbalance, and central sensitization, which amplify both mechanical and inflammatory stress on oral tissues.


Emerging evidence suggests that the condition is not confined to the oral cavity but reflects broader neuro-psycho-immunological dysregulation, linking central nervous system activity, autonomic tone, and peripheral tissue responses.


The endocannabinoid system (ECS) appears to play a regulatory role across many of these domains, including modulation of stress responses, sleep architecture, neuromuscular activity (e.g., bruxism), salivary function, and inflammatory processes. Dysregulation of ECS signaling may therefore contribute to both the development and persistence of this accelerated aging phenotype, while targeted modulation may offer a novel therapeutic avenue.


As an emerging construct, Premature Oral Aging highlights a shift from isolated dental pathology toward a systems-based understanding of oral health, where the mouth reflects broader patterns of physiological and behavioral dysregulation.

Disease Classification

Condition: Premature Oral Aging (Emerging Construct)
Disease Family:
Organ System: Digestive System
ICD-10 Chapter: Diseases of the digestive system
ICD-10 Code: K03.0

Premature Oral Aging (Emerging Construct) Symptoms:

Early enamel wear, dentin hypersensitivity, periodontal inflammation, gingival recession, temporomandibular discomfort, masticatory muscle tension, waking bruxism, sleep bruxism, xerostomia (dry mouth), reduced salivary flow, altered salivary quality, oral burning or discomfort, increased dental sensitivity, accelerated tooth surface loss, jaw fatigue, sleep disturbance, anxiety-related oral tension

Also known as:

Premature Oral Aging Syndrome

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol. 
  • THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
  • Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.

CBD Interaction with Pharmaceutical Drugs

  • Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
  • Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.

If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.

THC/CBD Interaction with Pharmaceutical Drugs

In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.

If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.

Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).

However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg
  • THC low dose:  0.5 mg to 5 mg
  • THC medium dose:  6 mg to 20 mg
  • THC high dose:  21 mg to 50+ mg

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg
  • CBD medium dose: 20 mg to 99 mg
  • CBD high dose:  100 mg to 800+ mg (upper limits tested ~1,500mg)
Top

Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.